Study of ARQ 197 in Hepatocellular Carcinoma (HCC)

Inclusion Criteria: * Confirmed HCC patients who are resistant to, intolerable to, or rejecting a systemic sorafenib therapy * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Child-Pugh classification A at the time of registration * Adequate bone marrow, liver, and renal functions within 14 days prior to registration Exclusion Criteria: * Prior therapy with a c-Met inhibitor (including ARQ 197) * Any systemic anti-tumor treatment or investigational agent within 2 weeks prior to registration. If the treatment/agent was antibody, within 4 weeks * Local treatment for malignancy within 4 weeks prior to registration * Major surgical procedure within 4 weeks prior to registration